TONIX Presentation November 2011

Corporate Presentation November 2011

Disclosures ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TONIX Pharmaceuticals Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Experienced Leadership Management Team Seth Lederman, MD Founder, CEO, Chairman Co-founder, Vela, Targent, Validus, Fontus Benjamin Selzer Chief Operating Officer Aton, Reliant, investment banking (Lehman Brothers & Banc of America Securities) Rhonda Rosen, CPA Chief Financial Officer CFO, Validus, Fontus , two divisions of CIGNA , PricewaterhouseCoopers

Accomplished Independent Board Board of Directors

Fibromyalgia Market Opportunity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* National Institutes of Health, U.S. Department of Health and Human Services ** Source: Frost & Sullivan Fibromyalgia Market Study, December 2010

Fibromyalgia: Vicious Cycle ,[object Object],[object Object],TNX-102 Pain Lyrica Sleep Disturbance No approved medications Depressed Mood Cymbalta

Comparison of Fibromyalgia Drugs Approved Treatments Pipeline Treatments * Jazz recently announced they are discontinuing the development of Rekinla ,[object Object],[object Object]

Cyclobenzaprine Has an Impressive Safety Record and is Widely Used ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* Source: Frost & Sullivan Fibromyalgia Market Study, December 2010

VLDC FM Pilot Study Results: Symptom Measures * Change from Baseline (week 8): tenderness measured by dolorimetry; HAD is the Hospital Anxiety and Depression Scale; HAD Depression is the HAD depression subscale 0% * Moldofsky et al., J. Rheum. December 2011: http://jrheum.org/content/early/2011/08/30/jrheum.110194.full.pdf+html ,[object Object],[object Object]

TNX-102: VLDC New Formulation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TNX-102: Development Plan ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TNX-102: Compelling Risk / Reward Profile ,[object Object],Risk Factor Commentary FDA Risk - Safety ,[object Object],[object Object],[object Object],[object Object],FDA Risk - Efficacy ,[object Object],[object Object],Commercial Risk ,[object Object],[object Object],[object Object],Reimbursement Risk ,[object Object],[object Object],Generic Competition ,[object Object],[object Object]

TNX-102: Compelling Risk / Reward Profile ,[object Object],[object Object],[object Object],[object Object]

TNX-105: VLDC for PTSD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* National Institutes of Mental Health & National Institutes of Health

FM & PTSD - Related Conditions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TONIX Pharmaceuticals Pipeline ,[object Object],Product Indication Status TNX-102 Fibromyalgia ,[object Object],[object Object],[object Object],[object Object],TNX-105 Post-Traumatic Stress Disorder ,[object Object],[object Object],[object Object],[object Object],TNX-201 Headache ,[object Object],[object Object],[object Object],TNX-301 Alcoholism ,[object Object],[object Object]

Exclusivity & Patents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Upcoming Milestones ,[object Object],Timing Milestones Related to TNX-102 December 2011 ,[object Object],Jan-Feb 2012 ,[object Object],Q1 2012 ,[object Object],Q3 2012 ,[object Object],Q1 2013 ,[object Object],Q2-Q3 2013 ,[object Object],[object Object]

Why Invest in TONIX? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TONIX Presentation November 2011

Recomendados

Recomendados

Mais conteúdo relacionado

Semelhante a TONIX Presentation November 2011

Semelhante a TONIX Presentation November 2011 (20)

Último

Último (20)

TONIX Presentation November 2011